6.40
Optimizerx Corp stock is traded at $6.40, with a volume of 324.69K.
It is up +5.79% in the last 24 hours and up +0.00% over the past month.
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
See More
Previous Close:
$6.05
Open:
$6.08
24h Volume:
324.69K
Relative Volume:
0.72
Market Cap:
$120.08M
Revenue:
$109.43M
Net Income/Loss:
$5.13M
P/E Ratio:
24.56
EPS:
0.2606
Net Cash Flow:
$18.91M
1W Performance:
-1.54%
1M Performance:
+0.00%
6M Performance:
-68.61%
1Y Performance:
-23.17%
Optimizerx Corp Stock (OPRX) Company Profile
Name
Optimizerx Corp
Sector
Industry
Phone
248-651-6558
Address
260 CHARLES STREET, WALTHAM, MI
Compare OPRX vs VEEV, TEM, BTSG, HQY, WAY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
OPRX
Optimizerx Corp
|
6.40 | 113.51M | 109.43M | 5.13M | 18.91M | 0.2606 |
|
VEEV
Veeva Systems Inc
|
167.30 | 25.98B | 3.20B | 908.91M | 1.39B | 5.4168 |
|
TEM
Tempus Ai Inc
|
56.41 | 8.89B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
46.01 | 8.89B | 12.91B | 104.80M | 394.69M | 0.8769 |
|
HQY
Healthequity Inc
|
83.67 | 6.87B | 1.31B | 215.20M | 408.32M | 2.4627 |
|
WAY
Waystar Holding Corp
|
24.68 | 4.30B | 1.10B | 112.09M | 283.19M | 0.6096 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-20-24 | Initiated | Stephens | Equal-Weight |
| Jul-25-24 | Resumed | B. Riley Securities | Buy |
| Apr-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Feb-02-23 | Resumed | B. Riley Securities | Buy |
| Nov-01-22 | Initiated | Stifel | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| Oct-18-21 | Resumed | B. Riley Securities | Buy |
| Apr-13-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-03-19 | Initiated | William Blair | Outperform |
View All
Optimizerx Corp Stock (OPRX) Latest News
OPRX Cuts Revenue Outlook: Temporary Reset or Structural Concern? - qz.com
OptimizeRx (OPRX) soars 5.9%: Is further upside left in the stock? - MSN
If You Invested $1,000 in Optimizerx Corp (OPRX) - Stock Titan
Whats the profit margin of OptimizeRx Corporation2026 Price Targets & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
OptimizeRx Corp. Receives Favorable Valuation Adjustment Amidst Profit Growth and High Institutional Confidence - Markets Mojo
OptimizeRx Adds Microsoft Health Leader to Board - TipRanks
OptimizeRx adds Microsoft Health exec to board of directors - Investing.com
Microsoft health leader joins OptimizeRx (OPRX) board as independent director - Stock Titan
OptimizeRx Appoints Microsoft Health & Life Sciences COO to Board - National Today
OptimizeRx Appoints Mary Varghese Presti to Board of Directors - Bitget
Are Investors Undervaluing OptimizeRx (OPRX) Right Now? - qz.com
Best Value Stocks to Buy for March 16th - Eastern Progress
What Makes OptimizeRx Corp. (OPRX) a Strong Momentum Stock: Buy Now? - MSN
OptimizeRx (OPRX) price target decreased by 40.41% to 14.79 - MSN
New Top-Rated Stocks to Buy for April 1st - Bitget
OPRX Should I Buy - Intellectia AI
OptimizeRx (NASDAQ: OPRX) switches auditors from UHY LLP to Grant Thornton - Stock Titan
OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Vanguard disaggregates holdings; OPRX parent reports 0 shares (OPRX) - Stock Titan
OPRX Technical Analysis & ETF Price Forecast - Intellectia AI
OptimizeRx (OPRX) Jumps 5.9%: Does the Stock Have More Room to Grow? - Bitget
Earnings call transcript: OptimizeRx Q4 2025 earnings beat forecasts, stock dips - Investing.com Australia
OPRX SEC FilingsOptimizerx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
OptimizeRx (OPRX) Soars 5.9%: Is Further Upside Left in the Stock? - finance.yahoo.com
Best Value Stocks to Buy for March 24th - sharewise.com
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates - MSN
Strength seen in OptimizeRx (OPRX): Can its 7.5% jump turn into more strength? - MSN
OPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Guidance Update: Can OptimizeRx Corporation sustain earnings growthEntry Point & Fast Entry Momentum Alerts - baoquankhu1.vn
OPRX Technical Analysis & Stock Price Forecast - Intellectia AI
How The OptimizeRx (OPRX) Narrative Is Shifting As Guidance Resets And Valuation Expectations Reprice - Yahoo Finance
OptimizeRx Corp. (NASDAQ:OPRX) Short Interest Down 16.4% in February - MarketBeat
Is OptimizeRx (OPRX) Stock Undervalued Right Now? - Yahoo Finance
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition? - MSN
OptimizeRx Corp. (OPRX) Q4 earnings and revenues beat estimates - MSN
OptimizeRx (OPRX) outlines AI-driven pharma marketing strategy and key risks - Stock Titan
Should you sell your OptimizeRx stock? - Cantech Letter
OptimizeRx Corporation Common Stock OPRX ) Stock Price Today & Analysis - Gotrade
OptimizeRx Corporation (NASDAQ:OPRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Optimizerx Corp Stock (OPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Optimizerx Corp Stock (OPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stelmakh Edward | Chief Finance & Strat Officer |
Dec 19 '25 |
Sale |
13.51 |
1,388 |
18,752 |
126,830 |
| Silvestro Stephen L | Chief Executive Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
6,546 |
0 |
195,462 |
| Odence-Ford Marion | Chief Legal & Admin Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
3,928 |
0 |
94,526 |
| Besch Doug | Chief Product & Tech Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
1,964 |
0 |
71,536 |
| Odence-Ford Marion | Chief Legal & Admin Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
6,649 |
0 |
92,550 |
| Silvestro Stephen L | Chief Executive Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
6,649 |
0 |
190,536 |
| Silvestro Stephen L | Chief Executive Officer |
Oct 03 '25 |
Sale |
18.75 |
1,620 |
30,375 |
188,916 |
| Stelmakh Edward | Chief Finance & Strat Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
16,623 |
0 |
127,387 |
| Besch Doug | Chief Product & Tech Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
3,325 |
0 |
70,555 |
| Spangler Patrick D | Director |
Aug 28 '25 |
Sale |
17.49 |
11,120 |
194,489 |
44,215 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):